Sphingolipids and Atherosclerosis: The Dual Role of Ceramide and Sphingosine-1-Phosphate
暂无分享,去创建一个
C. Pappone | Simona Coviello | M. Piccoli | F. Cirillo | P. Signorelli | P. La Rocca | A. Ghiroldi | L. Anastasia | P. Creo | P. Rota | A. Tarantino | Ivana Lavota | I. Lavota
[1] Li-ling Guo,et al. Novel insight on the role of Macrophages in atherosclerosis: Focus on polarization, apoptosis and efferocytosis. , 2022, International immunopharmacology.
[2] K. Alka,et al. Regulation of serine palmitoyl-transferase and Rac1–Nox2 signaling in diabetic retinopathy , 2022, Scientific Reports.
[3] W. Kuebler,et al. Sphingolipids in Atherosclerosis: Chimeras in Structure and Function , 2022, International journal of molecular sciences.
[4] Shiming Liu,et al. The Acid Sphingomyelinase Inhibitor Amitriptyline Ameliorates TNF-α-Induced Endothelial Dysfunction , 2022, Cardiovascular Drugs and Therapy.
[5] A. Cudnoch-Jędrzejewska,et al. Sphingolipid metabolism and signaling in cardiovascular diseases , 2022, Frontiers in Cardiovascular Medicine.
[6] G. Nickenig,et al. Ceramide Metabolism in Cardiovascular Disease: A Network With High Therapeutic Potential. , 2022, Arteriosclerosis, thrombosis, and vascular biology.
[7] B. Levkau,et al. Sphingosine-1-Phosphate (S1P) Lyase Inhibition Aggravates Atherosclerosis and Induces Plaque Rupture in ApoE−/− Mice , 2022, International journal of molecular sciences.
[8] D. Meyerholz,et al. Cordyceps inhibits ceramide biosynthesis and improves insulin resistance and hepatic steatosis , 2022, Scientific Reports.
[9] Duolu Li,et al. Lipidomics Analysis Reveals Protective Effect of Myriocin on Cerebral Ischemia/Reperfusion Model Rats , 2022 .
[10] Goon-Tae Kim,et al. De Novo Sphingolipid Biosynthesis in Atherosclerosis. , 2022, Advances in Experimental Medicine and Biology.
[11] P. Dörmann,et al. Activation of neutral sphingomyelinase 2 through hyperglycemia contributes to endothelial apoptosis via vesicle-bound intercellular transfer of ceramides , 2021, Cellular and Molecular Life Sciences.
[12] I. König,et al. Ceramide accumulation induces mitophagy and impairs β-oxidation in PINK1 deficiency , 2021, Proceedings of the National Academy of Sciences.
[13] K. Sandhoff,et al. Acid Sphingomyelinase, a Lysosomal and Secretory Phospholipase C, Is Key for Cellular Phospholipid Catabolism , 2021, International journal of molecular sciences.
[14] E. Fisher,et al. Fate and State of Vascular Smooth Muscle Cells in Atherosclerosis. , 2021, Circulation.
[15] I. D. Zelnik,et al. The Complex Tail of Circulating Sphingolipids in Atherosclerosis and Cardiovascular Disease , 2021, Journal of lipid and atherosclerosis.
[16] F. Lang,et al. Acid sphingomyelinase promotes SGK1-dependent vascular calcification. , 2021, Clinical science.
[17] C. Pappone,et al. The antithetic role of ceramide and sphingosine‐1‐phosphate in cardiac dysfunction , 2021, Journal of cellular physiology.
[18] F. Foufelle,et al. Dihydroceramides: Their emerging physiological roles and functions in cancer and metabolic diseases. , 2020, American journal of physiology. Endocrinology and metabolism.
[19] P. Jeppesen,et al. Endothelial dysfunction in small arteries and early signs of atherosclerosis in ApoE knockout rats , 2020, Scientific Reports.
[20] V. Saini,et al. Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis , 2020, Oxidative medicine and cellular longevity.
[21] Y. Zhang,et al. Associations between plasma ceramides and mortality in patients with coronary artery disease. , 2020, Atherosclerosis.
[22] D. Benvenuto,et al. Endothelial Sphingolipid De Novo Synthesis Controls Blood Pressure by Regulating Signal Transduction and NO via Ceramide , 2020, Hypertension.
[23] J. Rutter,et al. Reign in the membrane: How common lipids govern mitochondrial function. , 2020, Current opinion in cell biology.
[24] Zhiyuan Shen,et al. Myriocin and D-PDMP ameliorate atherosclerosis in ApoE-/-mice via reducing lipid uptake and vascular inflammation. , 2020, Clinical science.
[25] R. Paroni,et al. Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis. , 2020, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.
[26] R. Laaksonen,et al. Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography. , 2020, Diabetes & Metabolism.
[27] Hai-Jian Sun,et al. Role of Endothelial Dysfunction in Cardiovascular Diseases: The Link Between Inflammation and Hydrogen Sulfide , 2020, Frontiers in Pharmacology.
[28] R. Proia,et al. Sphingosine kinase-2 prevents macrophage cholesterol accumulation and atherosclerosis by stimulating autophagic lipid degradation , 2019, Scientific Reports.
[29] S. Summers,et al. Metabolic Messengers: ceramides , 2019, Nature Metabolism.
[30] C. Pappone,et al. Sphingolipid Synthesis Inhibition by Myriocin Administration Enhances Lipid Consumption and Ameliorates Lipid Response to Myocardial Ischemia Reperfusion Injury , 2019, Front. Physiol..
[31] D. Radzioch,et al. Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases: The importance of side chain. , 2019, Progress in lipid research.
[32] Qian Li,et al. ApoM-S1P Modulates Ox-LDL-Induced Inflammation Through the PI3K/Akt Signaling Pathway in HUVECs , 2018, Inflammation.
[33] S. Swendeman,et al. Sphingosine 1‐Phosphate Receptor 1 Signaling Maintains Endothelial Cell Barrier Function and Protects Against Immune Complex–Induced Vascular Injury , 2018, Arthritis & rheumatology.
[34] W. Lukiw,et al. The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and Neurodegeneration , 2018, Molecular Neurobiology.
[35] R. Proia,et al. Elevating Endogenous Sphingosine-1-Phosphate (S1P) Levels Improves Endothelial Function and Ameliorates Atherosclerosis in Low Density Lipoprotein Receptor-Deficient (LDL-R−/−) Mice , 2018, Thrombosis and Haemostasis.
[36] M. Perola,et al. Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths , 2018, European heart journal.
[37] F. Goñi,et al. The Physical Properties of Ceramides in Membranes. , 2018, Annual review of biophysics.
[38] E. Schuchman,et al. Ceramide and Ischemia/Reperfusion Injury , 2018, Journal of lipids.
[39] M. Kurano,et al. Sphingosine 1-Phosphate and Atherosclerosis , 2018, Journal of atherosclerosis and thrombosis.
[40] K. Rottner,et al. Cortactin: Cell Functions of A Multifaceted Actin-Binding Protein. , 2017, Trends in cell biology.
[41] R. de Caterina,et al. Endothelial permeability, LDL deposition, and cardiovascular risk factors—a review , 2018, Cardiovascular research.
[42] M. Nicholls. Plasma ceramides and cardiac risk , 2017 .
[43] F. Paris,et al. Plasma membrane reorganization links acid sphingomyelinase/ceramide to p38 MAPK pathways in endothelial cells apoptosis. , 2017, Cellular signalling.
[44] J. Chun,et al. Identification of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P1) as a Pathogenic Factor in Transient Focal Cerebral Ischemia , 2017, Molecular Neurobiology.
[45] T. Hla,et al. Vascular and Immunobiology of the Circulatory Sphingosine 1-Phosphate Gradient. , 2017, Annual review of physiology.
[46] Nicolas Foin,et al. Biomechanical stress in coronary atherosclerosis: emerging insights from computational modelling , 2016, European heart journal.
[47] J. Nofer,et al. High density lipoprotein (HDL)-associated sphingosine 1-phosphate (S1P) inhibits macrophage apoptosis by stimulating STAT3 activity and survivin expression. , 2015, Atherosclerosis.
[48] A. Engin. What Is Lipotoxicity? , 2017, Advances in experimental medicine and biology.
[49] W. Pan,et al. Acid Sphingomyelinase Mediates Oxidized-LDL Induced Apoptosis in Macrophage via Endoplasmic Reticulum Stress , 2016, Journal of atherosclerosis and thrombosis.
[50] A. Pandolfi,et al. Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. , 2016, Vascular pharmacology.
[51] A. Orekhov,et al. Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis , 2016, BioMed research international.
[52] A. Xu,et al. Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of the Endothelium-Derived Vasodilator Mediator. , 2016, Circulation research.
[53] J. Borén,et al. Sphingolipids Contribute to Human Atherosclerotic Plaque Inflammation. , 2016, Arteriosclerosis, thrombosis, and vascular biology.
[54] Kim Ekroos,et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol , 2016, European heart journal.
[55] M. Bennett,et al. Vascular Smooth Muscle Cells in Atherosclerosis. , 2016, Circulation research.
[56] P. Serruys,et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study. , 2015, Atherosclerosis.
[57] S. Mochida,et al. Inhibitor-1 and -2 of PP2A have preference between PP2A complexes. , 2015, Biochemical and biophysical research communications.
[58] Deborah Jones,et al. Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction In Vivo , 2015, Diabetes.
[59] S. Spiegel,et al. Revisiting the sphingolipid rheostat: Evolving concepts in cancer therapy. , 2015, Experimental cell research.
[60] Oliver Soehnlein,et al. Chemokines control mobilization, recruitment, and fate of monocytes in atherosclerosis. , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[61] Ira Tabas,et al. Recent insights into the cellular biology of atherosclerosis , 2015, The Journal of cell biology.
[62] Y. Hannun,et al. Critical determinants of mitochondria-associated neutral sphingomyelinase (MA-nSMase) for mitochondrial localization. , 2015, Biochimica et biophysica acta.
[63] Wei Chen,et al. Role of sphingosine-1-phosphate receptor 1 and sphingosine-1-phosphate receptor 2 in hyperglycemia-induced endothelial cell dysfunction. , 2015, International journal of molecular medicine.
[64] Tamara J. Blätte,et al. Phenotypic Regulation of the Sphingosine 1-Phosphate Receptor Miles Apart by G Protein-Coupled Receptor Kinase 2 , 2015, Biochemistry.
[65] S. Batra,et al. NADPH oxidases: an overview from structure to innate immunity-associated pathologies , 2014, Cellular and Molecular Immunology.
[66] H. Lei,et al. Akt/eNOS signaling pathway mediates inhibition of endothelial progenitor cells by palmitate-induced ceramide. , 2015, American journal of physiology. Heart and circulatory physiology.
[67] Julie K. Freed,et al. Ceramide Changes the Mediator of Flow-Induced Vasodilation From Nitric Oxide to Hydrogen Peroxide in the Human Microcirculation , 2014, Circulation research.
[68] T. Hla,et al. An update on the biology of sphingosine 1-phosphate receptors , 2014, Journal of Lipid Research.
[69] R. Erbel,et al. HDL-Bound Sphingosine 1-Phosphate (S1P) Predicts the Severity of Coronary Artery Atherosclerosis , 2014, Cellular Physiology and Biochemistry.
[70] Ann Saada,et al. Ceramide and the mitochondrial respiratory chain. , 2014, Biochimie.
[71] G. Shulman,et al. Ceramide-activated phosphatase mediates fatty acid-induced endothelial VEGF resistance and impaired angiogenesis. , 2014, The American journal of pathology.
[72] Si Jin,et al. Endogenous Ceramide Contributes to the Transcytosis of oxLDL across Endothelial Cells and Promotes Its Subendothelial Retention in Vascular Wall , 2014, Oxidative medicine and cellular longevity.
[73] Santiago Lamas,et al. Hydrogen peroxide signaling in vascular endothelial cells , 2014, Redox biology.
[74] B. Sellergren,et al. Lipidomic "deep profiling": an enhanced workflow to reveal new molecular species of signaling lipids. , 2014, Analytical chemistry.
[75] T. Byzova,et al. Oxidative stress in angiogenesis and vascular disease. , 2014, Blood.
[76] T. Ueland,et al. Matrix Metalloproteinase 7 Is Associated with Symptomatic Lesions and Adverse Events in Patients with Carotid Atherosclerosis , 2014, PloS one.
[77] W. März,et al. Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency , 2013, The Journal of clinical endocrinology and metabolism.
[78] Lihe Lu,et al. Ceramide Mediates Ox-LDL-Induced Human Vascular Smooth Muscle Cell Calcification via p38 Mitogen-Activated Protein Kinase Signaling , 2013, PloS one.
[79] K. Moore,et al. Macrophages in atherosclerosis: a dynamic balance , 2013, Nature Reviews Immunology.
[80] Y. Hannun,et al. A signaling cascade mediated by ceramide, src and PDGFRβ coordinates the activation of the redox-sensitive neutral sphingomyelinase-2 and sphingosine kinase-1. , 2013, Biochimica et biophysica acta.
[81] M. Kurano,et al. Liver involvement in sphingosine 1-phosphate dynamism revealed by adenoviral hepatic overexpression of apolipoprotein M. , 2013, Atherosclerosis.
[82] C. Weber,et al. KRP-203, Sphingosine 1-Phosphate Receptor Type 1 Agonist, Ameliorates Atherosclerosis in LDL-R−/− Mice , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[83] P. Hopkins,et al. Molecular biology of atherosclerosis. , 2013, Physiological reviews.
[84] J. Martín-Ventura,et al. HDL and endothelial protection , 2013, British journal of pharmacology.
[85] C. Christoffersen,et al. The Apolipoprotein M–Sphingosine-1-Phosphate Axis: Biological Relevance in Lipoprotein Metabolism, Lipid Disorders and Atherosclerosis , 2013, International journal of molecular sciences.
[86] R. Proia,et al. Shaping the landscape: metabolic regulation of S1P gradients. , 2013, Biochimica et biophysica acta.
[87] S. Saddoughi,et al. Diverse functions of ceramide in cancer cell death and proliferation. , 2013, Advances in cancer research.
[88] Yang Zhang,et al. Cross talk between ceramide and redox signaling: implications for endothelial dysfunction and renal disease. , 2013, Handbook of experimental pharmacology.
[89] G. Sakuta,et al. Sphingosine-1-phosphate: distribution, metabolism and role in the regulation of cellular functions. , 2013, Ukrains'kyi biokhimichnyi zhurnal.
[90] S. Barman,et al. From form to function: the role of Nox4 in the cardiovascular system , 2012, Front. Physio..
[91] H. Griffiths,et al. Palmitate promotes monocyte atherogenicity via de novo ceramide synthesis. , 2012, Free radical biology & medicine.
[92] Liping Wei,et al. FTY720 Protects Cardiac Microvessels of Diabetes: A Critical Role of S1P1/3 in Diabetic Heart Disease , 2012, PloS one.
[93] M. Riekkola,et al. Conformational changes of apoB-100 in SMase-modified LDL mediate formation of large aggregates at acidic pH[S] , 2012, Journal of Lipid Research.
[94] N. Ferreirós,et al. Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. , 2012, The international journal of biochemistry & cell biology.
[95] E. Abel,et al. Ceramide Mediates Vascular Dysfunction in Diet-Induced Obesity by PP2A-Mediated Dephosphorylation of the eNOS-Akt Complex , 2012, Diabetes.
[96] I. Petrache,et al. Mechanisms of lung endothelial barrier disruption induced by cigarette smoke: role of oxidative stress and ceramides. , 2011, American journal of physiology. Lung cellular and molecular physiology.
[97] L. Moreno,et al. Neutral sphingomyelinase, NADPH oxidase and reactive oxygen species. Role in acute hypoxic pulmonary vasoconstriction , 2011, Journal of cellular physiology.
[98] Zhou Junlin,et al. Inhibition of ceramide synthesis reverses endothelial dysfunction and atherosclerosis in streptozotocin-induced diabetic rats. , 2011, Diabetes research and clinical practice.
[99] B. Dahlbäck,et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M , 2011, Proceedings of the National Academy of Sciences.
[100] Jonathan D. Smith,et al. Sphingosine-1-Phosphate Receptor-2 Function in Myeloid Cells Regulates Vascular Inflammation and Atherosclerosis , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[101] I. Goldberg,et al. Sphingolipids and cardiovascular diseases: lipoprotein metabolism, atherosclerosis and cardiomyopathy. , 2011, Advances in experimental medicine and biology.
[102] G. Caimi,et al. [Oxidative stress and endothelial dysfunction]. , 2011, Minerva medica.
[103] E. Kremmer,et al. Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine‐1‐phosphate receptor S1P4 , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[104] Sarah Spiegel,et al. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature , 2010, Pharmacological Reviews.
[105] A. Bielawska,et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology , 2010, Journal of Lipid Research.
[106] Xiao-yong Lei,et al. Caveolae and caveolin-1 mediate endocytosis and transcytosis of oxidized low density lipoprotein in endothelial cells , 2010, Acta Pharmacologica Sinica.
[107] R. Erbel,et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease , 2010, Basic Research in Cardiology.
[108] A. Futerman,et al. Mammalian ceramide synthases , 2010, IUBMB life.
[109] Yang Zhang,et al. Ceramide in Redox Signaling and Cardiovascular Diseases , 2010, Cellular Physiology and Biochemistry.
[110] N. Mochizuki,et al. Sphingosine 1-Phosphate ( S 1 P ) Regulates Vascular Contraction via S 1 P 3 Receptor : Investigation Based on a New S 1 P 3 Receptor Antagonist , 2010 .
[111] F. Pecker,et al. Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. , 2009, Cardiovascular research.
[112] P. Hordijk,et al. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases , 2009, Journal of leukocyte biology.
[113] B. Levkau,et al. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. , 2008, Cardiovascular research.
[114] A. Verin,et al. Reprint of "The role of cytoskeleton in the regulation of vascular endothelial barrier function" [Microvascular Research 76 (2008) 202-207]. , 2009, Microvascular research.
[115] V. Taviani,et al. The mechanical triggers of plaque rupture: shear stress vs pressure gradient. , 2009, The British journal of radiology.
[116] K. Williams,et al. Acid Sphingomyelinase Promotes Lipoprotein Retention Within Early Atheromata and Accelerates Lesion Progression , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[117] S. Hammad,et al. High Density Lipoprotein-associated Sphingosine 1-Phosphate Promotes Endothelial Barrier Function* , 2008, Journal of Biological Chemistry.
[118] S. Wrenn,et al. Effect of sphingomyelinase-mediated generation of ceramide on aggregation of low-density lipoprotein. , 2008, Langmuir : the ACS journal of surfaces and colloids.
[119] T. Michel,et al. S1P and eNOS regulation. , 2008, Biochimica et biophysica acta.
[120] T. Hla,et al. The vascular S1P gradient-cellular sources and biological significance. , 2008, Biochimica et biophysica acta.
[121] S. Lorkowski,et al. HDL-Associated Lysosphingolipids Inhibit NAD(P)H Oxidase–Dependent Monocyte Chemoattractant Protein-1 Production , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[122] C. García-Rodríguez,et al. Selective attenuation of Toll-like receptor 2 signalling may explain the atheroprotective effect of sphingosine 1-phosphate. , 2008, Cardiovascular research.
[123] T. Littlewood,et al. Chronic Apoptosis of Vascular Smooth Muscle Cells Accelerates Atherosclerosis and Promotes Calcification and Medial Degeneration , 2008, Circulation research.
[124] L. Badimón,et al. Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: Effect of simvastatin , 2008, Thrombosis and Haemostasis.
[125] Y. Hannun,et al. The sphingolipid salvage pathway in ceramide metabolism and signaling. , 2008, Cellular signalling.
[126] Chad A. Corcoran,et al. Neutral Sphingomyelinase-3 Is a DNA Damage and Nongenotoxic Stress-Regulated Gene That Is Deregulated in Human Malignancies , 2008, Molecular Cancer Research.
[127] H. Bonkovsky,et al. Vascular Endothelium As a Contributor of Plasma Sphingosine 1-Phosphate , 2008, Circulation research.
[128] Takuya Shimizu,et al. Sphingosine 1-Phosphate Receptor 2 Negatively Regulates Neointimal Formation in Mouse Arteries , 2007, Circulation research.
[129] J. Borén,et al. Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update , 2007 .
[130] S. Dudek,et al. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. , 2007, Cellular Signalling.
[131] B. Levkau,et al. HDL and its sphingosine-1-phosphate content in cardioprotection , 2007, Heart Failure Reviews.
[132] E. Gulbins,et al. Acid sphingomyelinase and its redox amplification in formation of lipid raft redox signaling platforms in endothelial cells. , 2007, Antioxidants & redox signaling.
[133] J. Cyster,et al. Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate , 2007, Science.
[134] R. Proia,et al. Deafness and Stria Vascularis Defects in S1P2 Receptor-null Mice* , 2007, Journal of Biological Chemistry.
[135] Y. Hannun,et al. Redox regulation of neutral sphingomyelinase-1 activity in HEK293 cells through a GSH-dependent mechanism. , 2007, Archives of biochemistry and biophysics.
[136] G. Assmann,et al. FTY720, a Synthetic Sphingosine 1 Phosphate Analogue, Inhibits Development of Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice , 2007, Circulation.
[137] C. Weber,et al. Platelets as Immune Cells: Bridging Inflammation and Cardiovascular Disease , 2007, Circulation research.
[138] H. Katus,et al. Sphingosine-1-Phosphate Analogue FTY 720 Causes Lymphocyte Redistribution and Hypercholesterolemia in ApoE-Deficient Mice , 2007 .
[139] B. Levkau,et al. The Sphingosine-1-Phosphate Analogue FTY 720 Reduces Atherosclerosis in Apolipoprotein E – Deficient Mice , 2007 .
[140] K. Krause,et al. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. , 2007, Physiological reviews.
[141] M. Bennett,et al. The Emerging Role of Vascular Smooth Muscle Cell Apoptosis in Atherosclerosis and Plaque Stability , 2007, American Journal of Nephrology.
[142] Chulhee Choi,et al. Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. , 2006, Cardiovascular research.
[143] F. Visioli,et al. Age‐related changes in endothelial nitric oxide synthase phosphorylation and nitric oxide dependent vasodilation: evidence for a novel mechanism involving sphingomyelinase and ceramide‐activated phosphatase 2A , 2006, Aging cell.
[144] E. Gulbins,et al. TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis , 2006, Oncogene.
[145] S. Ben-Dor,et al. When Do Lasses (Longevity Assurance Genes) Become CerS (Ceramide Synthases)? , 2006, Journal of Biological Chemistry.
[146] R. Proia,et al. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. , 2006, The Biochemical journal.
[147] B. Kriem,et al. Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway , 2006, Neurobiology of Disease.
[148] Michal Levy,et al. nSMase2 activation and trafficking are modulated by oxidative stress to induce apoptosis. , 2006, Biochemical and biophysical research communications.
[149] U. Förstermann,et al. Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace , 2006, Circulation.
[150] E. Gulbins,et al. Lipid Raft Clustering and Redox Signaling Platform Formation in Coronary Arterial Endothelial Cells , 2006, Hypertension.
[151] P. Xia. High-Density Lipoproteins and Their Constituent, Sphingosine-1-Phosphate, Directly Protect the Heart Against Ischemia/Reperfusion Injury In Vivo via the S1P 3 Lysophospholipid Receptor , 2006 .
[152] T. Michel,et al. Rac 1 Modulates Sphingosine 1-Phosphate-mediated Activation of Phosphoinositide 3-Kinase / Akt Signaling Pathways in Vascular Endothelial Cells * , 2006 .
[153] S. Dudek,et al. Regulation of sphingosine 1‐phosphate‐induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and α‐actinin , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[154] G. Assmann,et al. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. , 2005, Trends in cardiovascular medicine.
[155] H. Cai. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. , 2005, Cardiovascular research.
[156] W. Stahl,et al. Nutritional, dietary and postprandial oxidative stress. , 2005, The Journal of nutrition.
[157] M. Hojjati,et al. Effect of Myriocin on Plasma Sphingolipid Metabolism and Atherosclerosis in apoE-deficient Mice* , 2005, Journal of Biological Chemistry.
[158] M. Hersberger,et al. Current understanding of the metabolism and biological actions of HDL , 2005, Current opinion in clinical nutrition and metabolic care.
[159] W. Erl,et al. Stable Knock-Down of the Sphingosine 1-Phosphate Receptor S1P1 Influences Multiple Functions of Human Endothelial Cells , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[160] Koichi Sato,et al. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. , 2005, Atherosclerosis.
[161] M. Rekhter,et al. Inhibition of Sphingomyelin Synthesis Reduces Atherogenesis in Apolipoprotein E–Knockout Mice , 2004, Circulation.
[162] A. Hermetter,et al. Role of ceramide in activation of stress-associated MAP kinases by minimally modified LDL in vascular smooth muscle cells. , 2004, Biochimica et biophysica acta.
[163] J. Keaney,et al. Role of oxidative modifications in atherosclerosis. , 2004, Physiological reviews.
[164] S. Itohara,et al. Role for Matrix Metalloproteinase-2 in Oxidized Low-Density Lipoprotein–Induced Activation of the Sphingomyelin/Ceramide Pathway and Smooth Muscle Cell Proliferation , 2004, Circulation.
[165] Sarah Spiegel,et al. Generation and metabolism of bioactive sphingosine‐1‐phosphate , 2004, Journal of cellular biochemistry.
[166] S. Dudek,et al. Interaction of cortactin and Arp2/3 complex is required for sphingosine-1-phosphate-induced endothelial cell remodeling. , 2004, Experimental cell research.
[167] E. Goetzl,et al. Sphingosine 1‐phosphate and its type 1 G protein‐coupled receptor: trophic support and functional regulation of T Lymphocytes , 2004, Journal of leukocyte biology.
[168] Jacek Bielawski,et al. Role for Mammalian Neutral Sphingomyelinase 2 in Confluence-induced Growth Arrest of MCF7 Cells* , 2004, Journal of Biological Chemistry.
[169] J. Chun,et al. Lysophospholipid receptors: signaling and biology. , 2004, Annual review of biochemistry.
[170] M. Zou,et al. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. , 2004, Endothelium : journal of endothelial cell research.
[171] G. Assmann,et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. , 2004, The Journal of clinical investigation.
[172] K. Claffey,et al. Phosphorylation and Action of the Immunomodulator FTY720 Inhibits Vascular Endothelial Cell Growth Factor-induced Vascular Permeability* , 2003, Journal of Biological Chemistry.
[173] J. Garcia,et al. Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. , 2003, American journal of physiology. Lung cellular and molecular physiology.
[174] K. Hanada,et al. Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. , 2003, Biochimica et biophysica acta.
[175] T. Michel,et al. Sphingosine 1-phosphate and control of vascular tone. , 2003, American journal of physiology. Heart and circulatory physiology.
[176] E. Clementi,et al. Activation of endothelial nitric-oxide synthase by tumor necrosis factor-alpha: a novel pathway involving sequential activation of neutral sphingomyelinase, phosphatidylinositol-3' kinase, and Akt. , 2003, Molecular pharmacology.
[177] A. Alonso,et al. Sphingomyelinases: enzymology and membrane activity , 2002, FEBS letters.
[178] U. Förstermann,et al. Dual Effect of Ceramide on Human Endothelial Cells: Induction of Oxidative Stress and Transcriptional Upregulation of Endothelial Nitric Oxide Synthase , 2002, Circulation.
[179] E. Kostenis,et al. Comparative analysis of human and rat S1P(5) (edg8): differential expression profiles and sensitivities to antagonists. , 2002, Biochemical pharmacology.
[180] Alfred H. Merrill,et al. De Novo Sphingolipid Biosynthesis: A Necessary, but Dangerous, Pathway* , 2002, The Journal of Biological Chemistry.
[181] D. Manning,et al. Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors. , 2002, Biochimica et biophysica acta.
[182] W. R. Taylor,et al. Superoxide Production and Expression of Nox Family Proteins in Human Atherosclerosis , 2002, Circulation.
[183] Y. Hannun,et al. Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[184] T. Hla,et al. Role of the Sphingosine 1-Phosphate Receptor EDG-1 in Vascular Smooth Muscle Cell Proliferation and Migration , 2001, Circulation research.
[185] A. Verin,et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. , 2001, The Journal of clinical investigation.
[186] E Vicaut,et al. Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-alpha is mediated by ceramide. , 2001, American journal of respiratory cell and molecular biology.
[187] D. Granger,et al. Adhesion molecules and their role in vascular disease. , 2001, American journal of hypertension.
[188] Pin-Lan Li,et al. Ceramide Reduces Endothelium-Dependent Vasodilation by Increasing Superoxide Production in Small Bovine Coronary Arteries , 2001, Circulation research.
[189] E. Clementi,et al. Activation of the Endothelial Nitric-oxide Synthase by Tumor Necrosis Factor-α , 2001, The Journal of Biological Chemistry.
[190] R. Kinscherf,et al. Ceramide induces aSMase expression: implications for oxLDL-induced apoptosis , 2001 .
[191] D. Brindley,et al. Platelet-released phospholipids link haemostasis and angiogenesis. , 2001, Cardiovascular research.
[192] Obeid,et al. The Sphingomyelin Cycle and the Second Messenger Function of Ceramide " , 2001 .
[193] M. Ui,et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. , 2000, The Biochemical journal.
[194] M. Colombini,et al. The Lipids C2- and C16-Ceramide Form Large Stable Channels , 2000, The Journal of Biological Chemistry.
[195] M. Kester,et al. Ceramide Directly Activates Protein Kinase C ζ to Regulate a Stress-activated Protein Kinase Signaling Complex* , 2000, The Journal of Biological Chemistry.
[196] A. Azzi,et al. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. , 2000, Circulation.
[197] S. Milstien,et al. Sphingosine‐1‐phosphate: signaling inside and out , 2000, FEBS letters.
[198] R. E. Pitas,et al. Class A Scavenger Receptor Up-regulation in Smooth Muscle Cells by Oxidized Low Density Lipoprotein* , 2000, The Journal of Biological Chemistry.
[199] Z. Fuks,et al. Ceramide mediates radiation‐induced death of endothelium , 2000, Critical care medicine.
[200] J. Keaney,et al. Redox control of vascular nitric oxide bioavailability. , 2000, Antioxidants & redox signaling.
[201] John G. Collard,et al. Rac Downregulates Rho Activity: Reciprocal Balance between Both Gtpases Determines Cellular Morphology and Migratory Behavior , 1999 .
[202] K. Claffey,et al. Vascular Endothelial Cell Adherens Junction Assembly and Morphogenesis Induced by Sphingosine-1-Phosphate , 1999, Cell.
[203] A. Barr,et al. Differential Coupling of the Sphingosine 1-Phosphate Receptors Edg-1, Edg-3, and H218/Edg-5 to the Gi, Gq, and G12 Families of Heterotrimeric G Proteins* , 1999, The Journal of Biological Chemistry.
[204] J. Boyle. Vascular smooth muscle cell apoptosis in atherosclerosis , 1999, International journal of experimental pathology.
[205] S. Kimura,et al. The novel sphingosine 1-phosphate receptor AGR16 is coupled via pertussis toxin-sensitive and -insensitive G-proteins to multiple signalling pathways. , 1999, The Biochemical journal.
[206] J. Gamble,et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[207] D. Choi,et al. Involvement of de Novo Ceramide Biosynthesis in Tumor Necrosis Factor-α/Cycloheximide-induced Cerebral Endothelial Cell Death* , 1998, The Journal of Biological Chemistry.
[208] C. H. Liu,et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. , 1998, Science.
[209] K. Williams,et al. Human Vascular Endothelial Cells Are a Rich and Regulatable Source of Secretory Sphingomyelinase , 1998, The Journal of Biological Chemistry.
[210] W. Edwards,et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. , 1998, Journal of the American College of Cardiology.
[211] R. Kolesnick,et al. Kinase Suppressor of Ras Is Ceramide-Activated Protein Kinase , 1997, Cell.
[212] J. Skepper,et al. FOAM CELL APOPTOSIS AND THE DEVELOPMENT OF THE LIPID CORE OF HUMAN ATHEROSCLEROSIS , 1996, The Journal of pathology.
[213] S. Spiegel,et al. Sphingolipid metabolism and cell growth regulation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[214] K. Williams,et al. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. , 1996, The Journal of clinical investigation.
[215] A. Nègre-Salvayre,et al. The Sphingomyelin-Ceramide Signaling Pathway Is Involved in Oxidized Low Density Lipoprotein-induced Cell Proliferation* , 1996, The Journal of Biological Chemistry.
[216] W D Wagner,et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[217] R. Cohen,et al. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle , 1994, Nature.
[218] Y. Hannun,et al. Programmed cell death induced by ceramide. , 1993, Science.
[219] I. Tabas,et al. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. , 1991, The Journal of biological chemistry.
[220] A. J. Valente,et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. , 1991, The Journal of clinical investigation.
[221] P. Vanhoutte,et al. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. , 1986, The American journal of physiology.
[222] R. Frye,et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. , 1975, Circulation.
[223] E. Smith,et al. Intimal and medial lipids in human aortas. , 1960, Lancet.